PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10511314
Filing Date	2005-05-17
First Named Inventor	David WALLACH
Art Unit	1652
Examiner Name	S. Swope
Attorney Docket Number	WALLACH33

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5854003		1998-12-29	Rothe et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	9737016	WO	A1	1997-10-09	Wallach et al.		☐
	2	0 578 932	EP	A2	1994-01-19	Sugamura et al.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10511314
	Filing Date	2005-05-17
	First Named Inventor	David WALLACH
	Art Unit	1652
	Examiner Name	S. Swope
	Attorney Docket Number	WALLACH33

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Rothe et al ,"A Novel Family of Putative Signal Transducers Associated with the Cytoplasmic Domain of the 75 kDa Tumor Necrosis Factor Receptor" Cell, 78: 681-692 (1994)	☐
	2	Smith.,"Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface" Science, 228:1315-17 (1984)	☐
	3	Fields et al.,"A novel genetic system to detect protein-protein interactions" Nature, 340: 265-6 (1989)	☐
	4	Akiba et al., "CD27, a Member of the Tumor Necrosis Factor Receptor Superfamily, Activates NF-kB and Stress-activated Protein Kinase/c-Jun N-terminal Kinase via TRAF2, TRAF5, and NF-kB-inducing Kinase" J. Biol Chem, 273 (21): 13353–13358 (1998)	☐
	5	Baldwin, Jr., "The NF-kB and IkB Proteins: New Discoveries and Insights" Annu. Rev. Immunol, 14: 649–83 (1996)	☐
	6	Ghosh et al., "NF-kB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses" Annu. Rev. Immunol, 16:225–60 (1998)	☐
	7	Karin et al., "PHOSPHORYLATION MEETS UBIQUITINATION: The Control of NF-kB Activity" Ann. Rev. Immunol, 18:621–663 (2000)	☐
	8	Canicio et al ,"Nuclear Factor kB-inducing Kinase and IkB Kinase-a Signal Skeletal Muscle Cell Differentiation" J Biol Chem, 276(23): 20228–33 (2001)	☐
	9	Darnay et al ," Activation of NF-kB by RANK Requires Tumor Necrosis Factor Receptor-associated Factor (TRAF) 6 and NF-kB-inducing Kinase" J Biol Chem, 274, 12:7724–31 (1999)	☐
	10	DiSanto et al., "Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain", Proc Natl Acad. Sci., 92:377-381 (1995)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10511314
	Filing Date	2005-05-17
	First Named Inventor	David WALLACH
	Art Unit	1652
	Examiner Name	S. Swope
	Attorney Docket Number	WALLACH33

	11	Fagarasan et al.,"Alymphoplasia (aly)-type Nuclear Factor kB–inducing (NIK) Kinase Causes Defects in Secondary Lymphoid Tissue Chemokine Receptor Signaling and Homing of Peritoneal Cells to the Gut-associated Lymphatic Tissue System", J. Exp. Med., Vol 191, 1477-86 (2000)	☐
	12	Foehr et al.,"The NF-kB-inducing Kinase Induces PC12 Cell Differentiation and Prevents Apoptosis", J Biol Chem, Vol. 275 (44): 34021–24 (2000)	☐
	13	Matsushima et al.,"Essential Role of Nuclear Factor (NF)-k B–inducing Kinase and Inhibitor of kB (IkB) Kinase a in NFk B Activation through Lymphotoxin b Receptor, but Not through Tumor Necrosis Factor Receptor I", J. Exp. Med. Volume 193, 5:631–636 (2001)	☐
	14	Mercurio et al.,"Multiple signals converging on NF-ICB", Current Opinion in Cell Biology, 11:226-232 (1999)	☐
	15	Natoli et al., "Tumor Necrosis Factor (TNF) Receptor 1 Signaling Downstream of TNF Receptor-associated Factor 2: NUCLEAR FACTOR kB (NFkB)-INDUCING KINASE REQUIREMENT FOR ACTIVATION OF ACTIVATING PROTEIN 1 AND NFkB BUT NOT OF c-Jun N-TERMINAL KINASE/STRESS-ACTIVATED PROTEIN KINASE" J Biol Chem, Vol. 272(42):26079–26082 (1997)	☐
	16	Pahl et al., "Activators and target genes of Rel/NF-kB transcription factors" Oncogene, Vol 18: 6853-6866 (1999)	☐
	17	Regnier et al.,"Identification and Characterization of an IkB Kinase" Cell, Vol. 90:373–383 (1997)	☐
	18	Noguchi et al.,"Interleukin-2 Receptor γ Chain Mutation Results in X-Linked Severe Combined Immunodeficiency in Humans" Cell, Vol. 73: 147-157 (1993)	☐
	19	Senftleben et al., "Activation by IKKa of a Second, Evolutionary Conserved, NF-kB Signaling Pathway" Science, Vol. 293:1495-9 (2001)	☐
	20	Shinkura et al.,"Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kb–inducing kinase" Nat Genet, Vol. 22:74-7 (1999)	☐
	21	Sylla et al., "Epstein–Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kB through a pathway that includes the NF-kB-inducing kinase and the IkB kinases IKKa and IKKb" Proc. Natl. Acad. Sci, Vol. 95.10106–10111 (1998)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10511314
	Filing Date	2005-05-17
	First Named Inventor	David WALLACH
	Art Unit	1652
	Examiner Name	S. Swope
	Attorney Docket Number	WALLACH33

	22	Takeuchi et al.,"Anatomy of TRAF2: DISTINCT DOMAINS FOR NUCLEAR FACTOR-kB ACTIVATION AND ASSOCIATION WITH TUMOR NECROSIS FACTOR SIGNALING PROTEINS" J Biol Chem,Vol. 271(33): 19935–42 (1996)	☐
	23	Uhlik et al.,"NF-kB-inducing Kinase and IkB Kinase Participate in Human T-cell Leukemia Virus I Tax-mediated NF-kB Activation" J Biol Chem, Vol. 273(33): 21132–21136 (1998)	☐
	24	Xiao et al.,"Negative Regulation of the Nuclear Factor kB-inducing Kinase by a cis-Acting Domain" J Biol Chem, Vol. 275(28): 21081–21085 (2000)	☐
	25	Xiao et al.,"NF-kB-Inducing Kinase Regulates the Processing of NF-kB2 p100" Molecular Cell, Vol. 7:401–409 (2001)	☐
	26	Yamada et al.,"Abnormal Immune Function of Hemopoietic Cells from Alymphoplasia (aly) Mice, a Natural Strain with Mutant NF-kB-Inducing Kina" J. Immunol, 165: 804–812 (2000)	☐
	27	Yamamoto et al., "Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer" The Journal of Clinical Investigation, Vol. 107(2): 135-142 (2001)	☐
	28	Yin et al., "Defective Lymphotoxin-b ReceptorÐInduced NF-kB Transcriptional Activity in NIK-DeÞcient Mice" Science, Vol 291:2162-2165 (2001)	☐
	29	Leonard et al.,"Role of the Common Cytokine Receptor (gamma)Chain in Cytokine Signaling and Lymphoid Development" Immunol Rev, No. 148: 97-114	☐
	30	Adang et al.,"The Contribution of Combinatorial Chemistry to Lead Generation: An Interim Analysis" Curr Med Chem, 8:985-998 (2001)	☐
	31	Miyawaki et al.,"A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice" Eur. J. Immunol, Vol. 24: 429-434 (1994)	☐
	32	Garceau et al., "Lineage-restricted.function of nuclear factor kappaB-inducing kinase (NIK) in transducing signals via CD40" J. Exp Med, Vol. 191:381-6. (2000)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10511314
	Filing Date	2005-05-17
	First Named Inventor	David WALLACH
	Art Unit	1652
	Examiner Name	S. Swope
	Attorney Docket Number	WALLACH33

	33	Geleziunas et al ,"Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases" Mol Cell Biol, Vol. 18: 5157-65. (1998).	☐
	34	Lin et al., "The protooncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases" Immunity, Vol 10:271-80 (1999)	☐
	35	Ling et al., "NF-kappaB-inducing kinase activates IKK-alpha 15 by phosphorylation of Ser-176" Proc Natl Acad Sci, Vol 95:3792-7. (1998)	☐
	36	Malinin et al., "MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-I" Nature, 385:540-4. (1997)	☐
	37	Matsumoto et al., "Involvement of distinct cellular 20 compartments in the abnormal lymphoid organogenesis in lymphotoxin-alphadeficient mice and alymphoplasia (aly) mice defined by the chimeric analysis" J. Immunol, 163, 1584-91 (1999)	☐
	38	Rothe et al., "Human NIK protein" DATABASE GENESEQ 'Online! EBI, Hinxton, Cambridgeshire, U.K. Database accession no. AAW82497 (1999-03-04)	☐
	39	Boldin et al., "Amino acid sequence of NF-kappaB inducing kinase" DATABASE GENESEQ 'Onlinel, EBI. Hinxton. Cambridgeshire, U.K.; Database accession no. AAW42402 (1998-04-15)	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.